VistaGen Therapeutics’ (VTGN) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of VistaGen Therapeutics (NASDAQ:VTGN) in a report released on Friday,Weiss Ratings reports.

A number of other research firms have also recently issued reports on VTGN. William Blair reiterated an “outperform” rating on shares of VistaGen Therapeutics in a report on Tuesday, October 21st. Wall Street Zen raised VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

VistaGen Therapeutics Price Performance

VTGN stock opened at $4.07 on Friday. The firm has a 50 day simple moving average of $3.57 and a two-hundred day simple moving average of $2.81. The stock has a market cap of $124.87 million, a PE ratio of -2.29 and a beta of 0.55. VistaGen Therapeutics has a one year low of $1.90 and a one year high of $4.52.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.47). The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.22 million. On average, research analysts expect that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of large investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC boosted its stake in shares of VistaGen Therapeutics by 246.4% during the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock valued at $1,052,000 after purchasing an additional 299,304 shares during the period. Jane Street Group LLC bought a new stake in VistaGen Therapeutics during the 2nd quarter valued at $190,000. Stempoint Capital LP boosted its position in VistaGen Therapeutics by 2.0% during the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after buying an additional 46,700 shares during the period. AdvisorShares Investments LLC boosted its position in VistaGen Therapeutics by 27.7% during the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock valued at $406,000 after buying an additional 44,000 shares during the period. Finally, Marshall Wace LLP bought a new stake in VistaGen Therapeutics in the 2nd quarter worth $69,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.